Regenerative medicine is the branch of translational research in tissue engineering and molecular biology, which develops the procedure of repair, replacement, and regeneration of the damaged cells, organs, and tissues.
These medicines comprise tissue engineering, regeneration and use of therapeutic steam cells, and development of artificial organs. It finds applications in the treatment of orthopedic, dermatology, cardiovascular, and neurodegenerative disorders. This branch of medicine also involves study of genes, biologics, and stem cells.
Tissue Engineering
In tissue engineering, biologically compatible scaffolds are implanted at a specific part of the body to form a new tissue. Stem cells have the capability to develop themselves into diverse cell types in the body and also help as an internal repair system in many tissues. Stem cells are unspecialized cells and they have the ability to renew themselves via cell division. Moreover, under certain experimental or physiologic circumstances, they could develop into tissue or organ-specific cells with special functions. For example, in some organs like bone marrow, stem cells repeatedly repair and replace the damaged tissues. They also provide possibilities of treating chronic diseases including heart disease and diabetes.
Achilles Tendonitis Pain Management
In September 2017, MiMedx declared that the company has received an approval from the United States Food and Drug Administration (FDA) enabling them to proceed with the phase 3 clinical study of “Achilles Tendonitis” for Investigational New Drug (IND).
Primary objective of this study is to determine the safe use of AmnioFix Injectable for treating severe Achilles Tendonitis. AmnioFix is a composite amniotic tissue membrane applicable to preserve the collagen matrix. This regenerative medicine can reduce the development of scar tissue and can boost the healing process. It can be utilized in soft tissue, tendon, and nerve applications.
Market Overview
According to Grand View Research, Inc.; the global regenerative medicine market is projected to achieve around USD 5.5 billion by 2025. High prevalence of genetic, neurodegenerative, and orthopedic diseases is one of the major market drivers. Impressive advancements in biotechnology may further impel the expansion over the forecast period (2014 to 2025). Introduction of policy reforms is also expected to create positive influence on the overall market growth.
Some of the leading companies in the market are AstraZeneca;Integra LifeSciences Corporation; F. Hoffmann-La Roche Ltd;Pfizer Inc; Baxter, and MiMedx Group, Inc.
In-Depth Research Report On Medium Regenerative Medicine Market:
https://www.grandviewresearch.com/industry-analysis/regenerative-medicine-market
No comments:
Post a Comment